Browse investments

Invest in Tyra Biosciences, Inc on Stash

Tyra Biosciences, Inc. is a precision oncology company. The Company is focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The Company uses it proprietary SNAP platform, which enables refinement of structural design through iterative molecular SNAPshots. The Company is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR), which are altered in approximately 7% of all cancers. Its lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. In addition, it has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase (RET), and FGFR4-related cancers.

To buy fractional shares of Tyra Biosciences, Inc stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Ticker: TYRA

Tyra Biosciences, Inc

$30.35

+19.16%

(1W)

$

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2024 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

TYRA Performance Breakdown

Share Price

$30.35

Today's change

0.73%

Year to date change (YTD)

13.29%

Dividend yield

0.0

Last dividend paid

N/A

Last dividend pay date

N/A

About TYRA

Tyra Biosciences, Inc. is a precision oncology company. The Company is focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The Company uses it proprietary SNAP platform, which enables refinement of structural design through iterative molecular SNAPshots. The Company is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR), which are altered in approximately 7% of all cancers. Its lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. In addition, it has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase (RET), and FGFR4-related cancers.

Tyra Biosciences, Inc Stock Ticker

TYRA

For more information

https://tyra.bio/

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2024 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

Invest in Tyra Biosciences, Inc on Stash

Tyra Biosciences, Inc. is a precision oncology company. The Company is focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The Company uses it proprietary SNAP platform, which enables refinement of structural design through iterative molecular SNAPshots. The Company is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR), which are altered in approximately 7% of all cancers. Its lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. In addition, it has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase (RET), and FGFR4-related cancers.

To buy fractional shares of Tyra Biosciences, Inc stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Certain companies are volatile

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

Tyra Biosciences, Inc stock news

CNBC

Trump's team races to come up with a Greenland takeover plan — here's what's at stake

U.S. Secretary of State Marco Rubio has said that he intends to convene with Danish officials next week to discuss Greenland. It comes amid growing concern across Europe about President Donald Trump's renewed threats to make the world's biggest island part of the United States.

about 12 hours ago

24/7 Wall Street

3 Top ETFs To Profit As Investors Move Away From Big Tech in 2026

Defensive stocks are defined as the stocks in companies that are grouped in sectors supplying goods and services in constant demand as essentials, and thus, do not follow trends of popularity.

about 8 hours ago

Business Insider

Microsoft reshuffles teams to bolster GitHub as AI coding and agent wars heat up

Microsoft is reshuffling teams to bolster its GitHub software development platform. It's part of a plan to overhaul GitHub to compete with AI coding tools, recent meeting audio shows.

about 12 hours ago

CNBC

Ford enters race to offer eyes-off driving tech, starting with $30,000 EV in 2028

Ford Motor plans to introduce eyes-off driving technology in 2028, starting with a $30,000 all-electric vehicle. The target brings Ford into a race against competitors such as Tesla, General Motors and Rivian Automotive to develop and broadly launch such systems.

about 22 hours ago

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.^†

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,⁸ recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.¹

Learn how to invest

Get professional advice and education at every step.

How to buy Tyra Biosciences, Inc stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

Tyra Biosciences, Inc’s share price is determined by its bid-ask spread, which is the difference between the price that buyers are willing to pay and the price that sellers are willing to accept. Tyra Biosciences, Inc’s price can fluctuate throughout the course of each trading day—when you buy Tyra Biosciences, Inc through Stash, we execute the market order during our next available trading window (we have two a day). At Stash, we don’t recommend trying to predict the market when buying investments. We believe it can be a better strategy to buy quality investments you believe in, then hang onto them.

Use our historic performance chart to see real-time Tyra Biosciences, Inc stock price and the Tyra Biosciences, Inc news feed to help further your research before investing in fractional shares with any dollar amount you choose.

Stash offers two subscription plans: Stash Growth and Stash+.

Each plan can help you reach different goals and offers a unique combination of financial accounts and features. All plans include access to a personal brokerage account—also known as your personal investment account. You can use your Stash personal portfolio to purchase any of the available investments on our platform, as well as access our suite of automatic saving and investing tools. Learn more about Stash pricing.

Once your market order of Tyra Biosciences, Inc stock is complete, you'll officially be a shareholder of Tyra Biosciences, Inc!